Mark M. Kockx

TL;DR: In this article, the authors performed a molecular analysis to identify oncogenic mutations (HRAS, KRAS, NRAS, CDKN2A, and TP53) in the lesions from patients treated with the BRAF inhibitor vemurafenib.

TL;DR: The Blueprint (BP) Programmed Death Ligand 1 (PD-L1) Immunohistochemistry Comparability Project is a pivotal academic/professional society and industrial collaboration to assess the feasibility of harmonizing the clinical use of five independently developed commercial PD-L 1 immunohistochemical assays.

TL;DR: It is demonstrated that phagocytosis of ACs is impaired in atherosclerotic plaques, which is at least partly attributed to oxidative stress and cytoplasmic saturation with indigestible material.

TL;DR: It is concluded that SMCs within human fatty streaks express BAX, which increases the susceptibility of these cells to undergo apoptosis, which could be important in the understanding of the transition of fatty streaks into atherosclerotic plaques, which are characterized by regions of cell death.

TL;DR: Evidence is provided that oxidative DNA damage and repair increase significantly in human atherosclerotic plaques and this is accompanied by the upregulation of DNA repair mechanisms.